Objective: This paper sorts out different risk-sharing agreements (RSAs) cases in the access and payment of innovative drugs, in order to provide a reference for the formulation of relevant policies in China.Methods: The paper applies case study based on different RSA types.Results: The rapid listing and medical insurance access of innovative drugs brings risks of budget overrun or less health effectiveness than the paid price. This article clarifies the concept of risk management for the access and payment of innovative drugs, and introduces three kinds of RSA cases, including finance-based agreements, performance-based agreements, and value-added agreements. RSA makes both drug suppliers and payers share budgetary risks and health risks, and helps to improve the access and payment management of innovative drugs.Conclusion: China can explore the use of RSA for risk management in innovative drug payment access, rely on pilot hospitals to conduct post-marketing re-evaluation of innovative drugs, and build an innovative drug re-evaluation system based on health technology assessment.
Key words
innovative drugs /
access /
payment /
risk management /
risk-sharing agreements
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 薛澜,周玲,朱琴.风险治理:完善与提升国家公共安全管理的基石[J].江苏社会科学,2008(06):7-11.
[2] 鲁全.本土创新药医保政策研究:现状、国际经验与政策建议[R].中国制药工业发展报告(2020).
[3] 杨晓胜,张旭升,曾理斌.风险分担协议在药物定价机制中应用的研究[J].中国卫生经济,2013,32(08):55-57.
[4] 常峰,崔鹏磊,张舰云,等.全球视角下药品风险分担协议政策分析[J].卫生经济研究,2016(08):39-44.
[5] Prasad V, Mailankody S .Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval[J]. JAMA Internal Medicine, 2017.
[6] 刘昭,朱雨蕾,郭武栋,张帆,陈金榆,王耀羚,李雪,赵琨,刘跃华.高价值创新药准入路径及支付策略的国际案例分析——以丙肝直接抗病毒药物为例[J].中国医疗保险,2020,144(09):77-81.
[7] Espín,J.C,Rovira J,Garcabuenoa L.Experiences and impact of European risk-sharing schemes focusing on oncology medicines[R]. 2011.
[8] Nicholas Florko.CMS finalizes long-sought rules for Medicare CAR-T coverage[EB/OL].https://www.statnews.com/2019/08/07/cms-finalizes-rules-medicare-car-t/
[9] 陈祥君,叶露.法国药品管理体制及其对中国的借鉴[J].中国卫生资源,2010,13.
[10] 卢碧香,关轶茹,张方.法国药品临床疗效和临床疗效改善评级管理及其借鉴启示[J].中国药物应用与监测,2018(2).
[11] Mary Caffrey.Cigna Reaches Pay-for-Performance Deals for PCSK9 Inhibitors[EB/OL]. https://www.ajmc.com/view/cigna-reaches-pay-for-performance-deals-for-pcsk9-inhibitors.
[12] 范必优,Siang Yun Ang.开启亚太地区伴随诊断的机遇[EB/OL]. https://www.lek.com/zh-hant/insights/ei/kaiqiyataidequbansuizhenduandejiyu.
